Suppr超能文献

使用靶向EED的双价化学降解剂降解多梳抑制复合物2

Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.

作者信息

Potjewyd Frances, Turner Anne-Marie W, Beri Joshua, Rectenwald Justin M, Norris-Drouin Jacqueline L, Cholensky Stephanie H, Margolis David M, Pearce Kenneth H, Herring Laura E, James Lindsey I

机构信息

Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

UNC HIV Cure Center, Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

出版信息

Cell Chem Biol. 2020 Jan 16;27(1):47-56.e15. doi: 10.1016/j.chembiol.2019.11.006. Epub 2019 Dec 9.

Abstract

Protein degradation via the use of bivalent chemical degraders provides an alternative strategy to block protein function and assess the biological roles of putative drug targets. This approach capitalizes on the advantages of small-molecule inhibitors while moving beyond the restrictions of traditional pharmacology. Here, we report a chemical degrader (UNC6852) that targets polycomb repressive complex 2 (PRC2). UNC6852 contains an EED226-derived ligand and a ligand for VHL which bind to the WD40 aromatic cage of EED and CRL2, respectively, to induce proteasomal degradation of PRC2 components, EED, EZH2, and SUZ12. Degradation of PRC2 with UNC6852 blocks the histone methyltransferase activity of EZH2, decreasing H3K27me3 levels in HeLa cells and diffuse large B cell lymphoma (DLBCL) cells containing EZH2 gain-of-function mutations. UNC6852 degrades both wild-type and mutant EZH2, and additionally displays anti-proliferative effects in this cancer model system.

摘要

通过使用二价化学降解剂进行蛋白质降解提供了一种替代策略,以阻断蛋白质功能并评估假定药物靶点的生物学作用。这种方法利用了小分子抑制剂的优势,同时突破了传统药理学的限制。在此,我们报告了一种靶向多梳抑制复合物2(PRC2)的化学降解剂(UNC6852)。UNC6852包含一个源自EED226的配体和一个VHL配体,它们分别与EED的WD40芳香笼和CRL2结合,以诱导PRC2组分EED、EZH2和SUZ12的蛋白酶体降解。用UNC6852降解PRC2可阻断EZH2的组蛋白甲基转移酶活性,降低HeLa细胞和含有EZH2功能获得性突变的弥漫性大B细胞淋巴瘤(DLBCL)细胞中的H3K27me3水平。UNC6852可降解野生型和突变型EZH2,并且在该癌症模型系统中还表现出抗增殖作用。

相似文献

2
EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.EED 靶向 PROTACs 降解 PRC2 复合物中的 EED、EZH2 和 SUZ12。
Cell Chem Biol. 2020 Jan 16;27(1):41-46.e17. doi: 10.1016/j.chembiol.2019.11.004. Epub 2019 Nov 27.

引用本文的文献

7
Characteristic roadmap of linker governs the rational design of PROTACs.连接子的特征路线图决定了PROTACs的合理设计。
Acta Pharm Sin B. 2024 Oct;14(10):4266-4295. doi: 10.1016/j.apsb.2024.04.007. Epub 2024 Apr 11.
9
PROTACs Targeting Epigenetic Proteins.靶向表观遗传蛋白的PROTACs
Acta Mater Med. 2023 Oct 26;2(4):409-429. doi: 10.15212/amm-2023-0039. Epub 2023 Dec 6.
10
Paralogue-Selective Degradation of the Lysine Acetyltransferase EP300.赖氨酸乙酰转移酶EP300的旁系同源物选择性降解
JACS Au. 2024 Jul 29;4(8):3094-3103. doi: 10.1021/jacsau.4c00442. eCollection 2024 Aug 26.

本文引用的文献

1
Targeting protein methylation: from chemical tools to precision medicines.靶向蛋白质甲基化:从化学工具到精准药物。
Cell Mol Life Sci. 2019 Aug;76(15):2967-2985. doi: 10.1007/s00018-019-03147-9. Epub 2019 May 18.
3
First targeted protein degrader hits the clinic.首个靶向蛋白降解剂进入临床阶段。
Nat Rev Drug Discov. 2019 Mar 6. doi: 10.1038/d41573-019-00043-6.
4
Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs. cereblon 与 vhl :使用 protacs 相互劫持 e3 连接酶。
Bioorg Med Chem. 2019 Jun 15;27(12):2466-2479. doi: 10.1016/j.bmc.2019.02.048. Epub 2019 Feb 22.
7
The PROTAC technology in drug development.蛋白水解靶向嵌合体技术在药物研发中的应用。
Cell Biochem Funct. 2019 Jan;37(1):21-30. doi: 10.1002/cbf.3369. Epub 2019 Jan 2.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验